Stay updated on Phase II Pembrolizumab Plus GVD Clinical Trial

Sign up to get notified when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase II Pembrolizumab Plus GVD Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    A minor site-wide revision (Revision: v3.4.2) was added, and the interim funding-status notice along with the previous revision entry (Revision: v3.4.1) were removed. There are no changes to study content or user interactions; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T04:43:45.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice regarding government funding and NIH Clinical Center status. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T05:30:47.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary display option and updated update-related metadata (including capitalization of 'Last Update Submitted that Met QC Criteria' and the 'Last Update Posted' label). The page revision is now v3.4.0, replacing v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T03:28:21.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:31:47.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    A consolidated Locations section lists Florida, New Jersey, and New York sites, replacing the previous separate location subsections. The revision tag updates to v3.3.3 and the old state location sections are removed.
    Difference
    0.3%
    Check dated 2025-12-23T17:27:09.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Eligibility criteria now require lab values from before Cycle 1 of Pembrolizumab-GVD. Renal function is assessed by eGFR (≥60 mL/min), replacing prior CrCl/GFR language.
    Difference
    0.3%
    Check dated 2025-12-09T01:11:39.000Z thumbnail image

Stay in the know with updates to Phase II Pembrolizumab Plus GVD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase II Pembrolizumab Plus GVD Clinical Trial page.